速効型インスリン市場- 世界の産業規模、動向、機会、予測、薬剤別、用途別、地域別、競合別、2019年～2029年

速効型インスリンの世界市場は、2023年に67億5,000万米ドルと評価され、2029年までのCAGRは4.05%で、予測期間中に目覚ましい成長を予測しています。

速効型インスリン市場は、糖尿病患者のニーズに応える、世界のヘルスケアセクターのダイナミックで重要なコンポーネントです。速効型インスリンは、通常のインスリンまたは速効型インスリンとしても知られ、特に食事時の血糖値管理において極めて重要な役割を果たしています。この市場は、速効型インスリン製剤の生産、流通、利用を中心に展開されており、迅速かつ効率的なインスリン作用を必要とする糖尿病患者にとって不可欠なものです。速効型インスリン市場を牽引する主な要因の1つは、世界の糖尿病有病率の上昇です。糖尿病がより一般的になるにつれ、特に座りがちなライフスタイルや肥満の増加に伴い、速効型インスリンの需要が急増しています。このインスリン製剤は、食後のグルコースレベルをコントロールするのに不可欠であり、食事の時間に合わせて迅速に作用が発現します。市場は、糖尿病患者の効果的なグルコース管理を確実にするために、様々な製剤や送達方法を提供することで、この需要の高まりに対応しています。インスリン送達システムと製剤の技術的進歩は、速効型インスリン市場のもう一つの重要な促進要因です。インスリンペン、ポンプ、より精製されたインスリンアナログなどの技術革新は、インスリン投与の利便性と精度を向上させる。これらの進歩は、服薬アドヒアランスの向上、注射に関連する不快感の軽減、全体的な血糖コントロールの改善に寄与するため、患者は恩恵を受ける。市場各社は斬新な技術や製剤の導入にしのぎを削り、市場の進化を促す競合情勢を醸成しています。さらに、個別化された患者中心の糖尿病治療が重視されるようになったことも、市場に影響を与えています。インスリン療法を個人のニーズやライフスタイルに合わせて調整することが優先され、より患者に優しいインスリン送達オプションの開発が進んでいます。これにはデバイスだけでなくインスリン製剤自体も含まれ、生理的なインスリン反応を模倣する薬物動態の最適化に焦点が当てられています。速効型インスリン市場はこのような動向に合わせて、ますます多様化する患者集団の嗜好や要求に合わせて多様な選択肢を提供しています。

市場力学は、インスリン製剤を管理する規制環境によっても形成されます。厳しい規制基準が速効型インスリン製剤の安全性、有効性、品質を保証しています。市場開拓者はこれらの基準を満たすために研究開発に投資する一方、新興国市場での承認取得の機会を探っています。規制順守と品質基準の遵守は、市場の競合情勢や医療従事者と患者の信頼度に影響を与える重要な側面です。さらに、速効型インスリン市場は、次世代インスリン製剤の開発を目指した活発な研究活動によって特徴付けられています。これには、生理的インスリン反応をより忠実に模倣し、より正確で迅速な作用発現を実現する超速効型インスリン製剤の開発への取り組みが含まれます。製剤やデリバリーシステムの改良の追求は、患者の糖尿病管理全般を向上させるという市場プレイヤーのコミットメントを反映しています。

市場促進要因

糖尿病有病率の上昇

個別化された糖尿病治療

主な市場課題

コストの上昇

アクセス格差

アドヒアランスの問題

技術格差

主要市場動向

先進デリバリーシステム

バイオシミラー市場の拡大

デジタルヘルス統合

持続グルコースモニタリングの提携

セグメント別インサイト

薬剤別インサイト

用途別インサイト

地域別インサイト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 速効型インスリンの世界市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別（アピドラ、ノボログ、ヒューマログ、ノボリン、その他）
  • 用途別（1型糖尿病、2型糖尿病）
  • 地域別
  • 企業別（2023年）
• 市場マップ
  • 薬剤別
  • 用途別
  • 地域別

第5章 アジア太平洋地域の速効型インスリン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別
  • 用途別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の速効型インスリン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別
  • 用途別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の速効型インスリン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別
  • 用途別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の速効型インスリン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別
  • 用途別
  • 国別
• 南米：：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの速効型インスリン市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 薬剤別
  • 用途別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場動向と発展

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品発表
• 合併・買収

第12章 速効型インスリンの世界市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Novo Nordisk AS
• Sanofi SA
• Eli Lilly Co
• Biocon Ltd
• Wockhardt Ltd
• Boehringer Ingelheim International GmbH
• Julphar Pharma Inc
• United Laboratories International Holdings Limited
• Tonghua Dongbao Pharmaceutical Co. Ltd.

第15章 戦略的提言

第16章 免責事項

Global Short-Acting Insulin Market was valued at USD 6.75 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.05% through 2029. The Short-Acting Insulin Market is a dynamic and crucial component of the global healthcare sector, catering to the needs of individuals with diabetes. Short-acting insulin, also known as regular or fast-acting insulin, plays a pivotal role in managing blood glucose levels, particularly during mealtime. This market revolves around the production, distribution, and utilization of short-acting insulin products, which are indispensable for people with diabetes who require rapid and efficient insulin action.One of the primary factors driving the Short-Acting Insulin Market is the escalating prevalence of diabetes worldwide. As diabetes becomes more prevalent, especially with the rise in sedentary lifestyles and obesity, the demand for short-acting insulin has surged. This insulin variant is essential for controlling postprandial glucose levels, offering a rapid onset of action that aligns with mealtime requirements. The market responds to this growing demand by providing various formulations and delivery methods to ensure effective glucose management for individuals with diabetes. Technological advancements in insulin delivery systems and formulations represent another significant driver in the Short-Acting Insulin Market. Innovations such as insulin pens, pumps, and more refined insulin analogs enhance the convenience and precision of insulin administration. Patients benefit from these advancements as they contribute to improved adherence, reduced injection-related discomfort, and better overall glycemic control. Manufacturers compete to introduce novel technologies and formulations, fostering a competitive landscape that propels the market's evolution. Moreover, the market is influenced by an increased emphasis on personalized and patient-centric diabetes care. Tailoring insulin regimens to individual needs and lifestyles is a priority, leading to the development of more patient-friendly insulin delivery options. This includes not only the devices but also the insulin formulations themselves, with a focus on optimizing pharmacokinetics to mimic the physiological insulin response. The Short-Acting Insulin Market aligns with these trends, offering diverse options to suit the preferences and requirements of an increasingly diverse patient population.

Market dynamics are also shaped by the regulatory environment governing insulin products. Stringent regulatory standards ensure the safety, efficacy, and quality of short-acting insulin formulations. Market players invest in research and development to meet these standards while also exploring opportunities for regulatory approval in emerging markets. Regulatory compliance and adherence to quality standards are critical aspects that influence the market's competitive landscape and the level of trust among healthcare professionals and patients. Furthermore, the Short-Acting Insulin Market is characterized by robust research activities aimed at developing next-generation insulin products. This includes efforts to create ultra-rapid-acting insulins that more closely mimic the physiological insulin response, providing an even more precise and rapid onset of action. The pursuit of improved formulations and delivery systems reflects the commitment of market players to enhance the overall diabetes management experience for patients.

Key Market Drivers

Rising Diabetes Prevalence

The driving force behind the growth of the Short-Acting Insulin Market is the escalating prevalence of diabetes on a global scale. With diabetes reaching epidemic proportions, particularly type 2 diabetes linked to sedentary lifestyles and obesity, the demand for effective insulin management has surged. Short-acting insulin, known for its rapid onset and crucial role in controlling postprandial glucose levels, becomes indispensable for individuals requiring immediate and efficient insulin action during mealtime.

As more people are diagnosed with diabetes, the need for precise glucose control becomes paramount to prevent complications. Short-acting insulin addresses this need by offering a rapid response to elevated blood glucose levels after meals. The market aligns with this demand by providing various formulations and delivery methods to cater to diverse patient needs.

The rising prevalence of diabetes also amplifies the market's significance in preventing diabetes-related complications. Efficient glucose management, achieved through short-acting insulin, is crucial for preventing cardiovascular issues, kidney problems, and other diabetes-related complications. Consequently, the Short-Acting Insulin Market becomes an integral component of diabetes care, ensuring that individuals have access to advanced and effective insulin solutions to better manage their condition and improve their overall quality of life.

Personalized Diabetes Care

The Short-Acting Insulin Market is experiencing a transformative shift driven by the increasing emphasis on personalized diabetes care. As healthcare moves towards a more patient-centric approach, tailoring diabetes management strategies to individual needs becomes paramount, and short-acting insulin plays a pivotal role in this paradigm.

Personalized diabetes care recognizes the unique characteristics of each patient, including lifestyle, dietary habits, and insulin sensitivity. Short-acting insulin formulations and delivery methods are diversified to accommodate these individual factors, ensuring a tailored and precise approach to glycemic control. This customization not only enhances treatment efficacy but also improves patient adherence and satisfaction. Advanced insulin delivery systems, such as insulin pens and pumps, provide patients with options that align with their preferences and lifestyle. These technologies contribute to a more convenient and comfortable insulin administration experience, fostering better adherence to treatment plans. Additionally, the development of novel insulin analogs with specific pharmacokinetic profiles allows healthcare providers to fine-tune insulin regimens based on individual patient needs, optimizing glycemic control.

The shift towards personalized diabetes care represents a paradigmatic evolution in diabetes management. The Short-Acting Insulin Market, by offering a diverse range of options that can be tailored to individual requirements, stands at the forefront of this transformation, ensuring that patients receive not only effective but also personalized solutions for their diabetes treatment. This trend is likely to shape the future landscape of diabetes care, emphasizing precision and patient-centric approaches within the Short-Acting Insulin Market.

Key Market Challenges

Rising Costs

The Short-Acting Insulin Market faces a significant challenge in the form of rising costs associated with production and research. The complexity of insulin manufacturing processes, coupled with the need for continual research and development for innovative formulations and delivery systems, contributes to increased production expenses. These rising costs impact the affordability of short-acting insulin, potentially limiting access for patients. As insulin is a life-sustaining medication for those with diabetes, addressing the challenge of escalating costs becomes crucial to ensure widespread availability and affordability, ultimately promoting better glycemic control and overall diabetes management.

Access Disparities

Access disparities pose a substantial challenge in the Short-Acting Insulin Market, contributing to unequal global health outcomes. Limited access to affordable insulin in certain regions creates significant disparities in diabetes management. Economic factors, healthcare infrastructure variations, and regulatory hurdles contribute to these disparities. The high costs associated with insulin production and distribution further exacerbate the accessibility issue, preventing many individuals from obtaining essential short-acting insulin. Addressing access challenges is crucial to ensure that all individuals with diabetes, regardless of geographic location or socioeconomic status, can access and afford the life-saving medication needed for effective glycemic control and overall well-being.

Adherence Issues

Adherence issues present a significant challenge for the Short-Acting Insulin Market, impacting the effectiveness of diabetes management. Patient adherence to prescribed insulin regimens, including timing and dosage, is crucial for achieving optimal glycemic control. Factors such as fear of injections, inconvenience, or lack of understanding can contribute to non-adherence. This challenge may lead to suboptimal blood glucose control, increasing the risk of complications. Strategies addressing patient education, personalized treatment plans, and the development of more user-friendly delivery systems are essential to overcome adherence issues, ensuring that individuals with diabetes can effectively incorporate short-acting insulin into their daily routines.

Technological Gaps

Technological gaps pose a challenge for the Short-Acting Insulin Market, impacting the widespread adoption of advanced insulin delivery systems. While innovations like insulin pumps and pens enhance convenience and precision, accessibility remains an issue in certain regions. Limited technological infrastructure and awareness hinder the adoption of these advancements, leading to disparities in diabetes care. Bridging technological gaps requires efforts to improve healthcare infrastructure, educate healthcare providers and patients, and ensure affordability of advanced insulin delivery technologies. Overcoming these challenges is crucial to ensure that individuals globally can benefit from the latest technological advancements in short-acting insulin therapy, optimizing diabetes management.

Key Market Trends

Advanced Delivery Systems

Advanced delivery systems represent a prominent trend in the Short-Acting Insulin Market, reflecting a shift towards enhanced patient experience and improved glycemic control. Innovations such as insulin pens, pumps, and smart devices are gaining traction, offering convenient and precise administration. These technologies provide more flexibility, reduce injection-related discomfort, and improve overall adherence to insulin regimens. The trend emphasizes a patient-centric approach, focusing on user-friendly solutions that align with individual preferences and lifestyles. As the market continues to prioritize technological advancements, the integration of more sophisticated delivery systems is expected to play a pivotal role in shaping the future landscape of short-acting insulin therapy.

Biosimilar Market Expansion

The expansion of the biosimilar market is a notable trend in the Short-Acting Insulin Market, offering increased options for individuals with diabetes. Biosimilar short-acting insulin products, which mimic the properties of existing insulin formulations, contribute to market competitiveness and affordability. This trend fosters a more competitive landscape, potentially lowering overall insulin costs and enhancing accessibility. As more biosimilars receive regulatory approval and enter the market, the trend supports the goal of providing diverse and cost-effective insulin options. The biosimilar market expansion aligns with efforts to address the rising costs and access disparities associated with short-acting insulin, making diabetes management more sustainable for a broader population.

Digital Health Integration

Digital health integration is a prominent trend shaping the Short-Acting Insulin Market, bringing technology into the forefront of diabetes management. The incorporation of digital health tools, such as smartphone apps, continuous glucose monitoring (CGM) systems, and smart insulin pens, enhances the overall patient experience. These technologies provide real-time data, personalized insights, and convenient ways to monitor and administer short-acting insulin. The trend fosters a more connected and proactive approach to diabetes care, empowering individuals to make informed decisions. As the Short-Acting Insulin Market embraces digital solutions, the synergy between technology and insulin therapy is poised to revolutionize diabetes management for improved outcomes.

Continuous Glucose Monitoring Collaboration

The trend of collaboration with continuous glucose monitoring (CGM) systems is reshaping the Short-Acting Insulin Market. Integration with CGM technologies allows for real-time glucose monitoring, enabling more precise insulin dosing decisions. This collaborative trend enhances the synergy between short-acting insulin administration and glucose control, optimizing glycemic management. Patients benefit from a more streamlined and personalized approach, as CGM data informs insulin dosing adjustments in response to fluctuating glucose levels. The trend reflects a commitment to comprehensive diabetes care, emphasizing the importance of combining advanced insulin therapies with continuous monitoring solutions for more effective and patient-centric management of diabetes.

Segmental Insights

Drugs Insights

Basedon the Drugs, Apidra, a brand of short-acting insulin (insulin glulisine), has established dominance in the market due to its rapid onset and shorter duration of action, making it an effective option for controlling postprandial glucose levels. Its quick response aligns with mealtime requirements, providing flexibility and precision in insulin dosing. Apidra's formulation reduces the risk of hypoglycemia and offers a more convenient treatment option for individuals with diabetes. With a proven track record and widespread acceptance, Apidra has become a preferred choice for healthcare providers, contributing to its dominance in the Short-Acting Insulin Market.

Application Insights

Type 1 diabetes dominance in the Short-Acting Insulin Market is rooted in the essential role short-acting insulin plays in managing this autoimmune condition. Individuals with type 1 diabetes lack natural insulin production, requiring external insulin to regulate glucose levels. Short-acting insulin, with its rapid onset, is crucial for addressing immediate postprandial glucose spikes. The precision in timing and dosage aligns with the dynamic insulin needs in type 1 diabetes, providing effective control. The prevalence of type 1 diabetes globally sustains the demand for short-acting insulin, solidifying its dominance in the market as a foundational component of type 1 diabetes management.

Regional Insights

North America's dominance in the Short-Acting Insulin Market is attributed to several factors. The region exhibits a high prevalence of diabetes, creating a substantial patient pool requiring insulin therapy. Robust healthcare infrastructure, advanced research facilities, and a well-established regulatory framework contribute to the development and adoption of innovative short-acting insulin formulations and delivery systems. Additionally, favorable reimbursement policies and a high level of awareness among healthcare professionals and patients enhance the market's growth. The presence of major pharmaceutical companies focusing on diabetes management further cements North America's position as a dominant player in the Short-Acting Insulin Market.

Key Market Players

Novo Nordisk AS

Sanofi SA

Eli Lilly Co

Biocon Ltd

Wockhardt Ltd

Boehringer Ingelheim International GmbH

Julphar Pharma Inc

United Laboratories International Holdings Limited

Tonghua Dongbao Pharmaceutical Co. Ltd.

Report Scope:

In this report, the GlobalShort-Acting InsulinMarket has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short-Acting Insulin Market,By Drugs:

• Apidra
• Novolog
• Humalog
• Novolin
• Others

Short-Acting Insulin Market,By Application:

• Type 1 Diabetes
• Type 2 Diabetes

Short-Acting Insulin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Short-Acting Insulin Market.

Available Customizations:

Global Short-Acting Insulin market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Short-Acting Insulin Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Drugs (Apidra, Novolog, Humalog, Novolin, Others)
  • 4.2.2.By Application (Type 1 Diabetes, Type 2 Diabetes)
  • 4.2.3.By Region
  • 4.2.4.By Company (2023)
• 4.3.Market Map
  • 4.3.1.By Drugs
  • 4.3.2.By Application
  • 4.3.3.By Region

5.Asia Pacific Short-Acting Insulin Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Drugs
  • 5.2.2.By Application
  • 5.2.3.By Country
• 5.3.Asia Pacific: Country Analysis
  • 5.3.1.China Short-Acting Insulin Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Drugs
      • 5.3.1.2.2.By Application
  • 5.3.2.India Short-Acting Insulin Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Drugs
      • 5.3.2.2.2.By Application
  • 5.3.3.Australia Short-Acting Insulin Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Drugs
      • 5.3.3.2.2.By Application
  • 5.3.4.Japan Short-Acting Insulin Market Outlook
    • 5.3.4.1.Market Size Forecast
      • 5.3.4.1.1.By Value
    • 5.3.4.2.Market Share Forecast
      • 5.3.4.2.1.By Drugs
      • 5.3.4.2.2.By Application
  • 5.3.5.South Korea Short-Acting Insulin Market Outlook
    • 5.3.5.1.Market Size Forecast
      • 5.3.5.1.1.By Value
    • 5.3.5.2.Market Share Forecast
      • 5.3.5.2.1.By Drugs
      • 5.3.5.2.2.By Application

6.Europe Short-Acting Insulin Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Drugs
  • 6.2.2.By Application
  • 6.2.3.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Short-Acting Insulin Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Drugs
      • 6.3.1.2.2.By Application
  • 6.3.2.Germany Short-Acting Insulin Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Drugs
      • 6.3.2.2.2.By Application
  • 6.3.3.Spain Short-Acting Insulin Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Drugs
      • 6.3.3.2.2.By Application
  • 6.3.4.Italy Short-Acting Insulin Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Drugs
      • 6.3.4.2.2.By Application
  • 6.3.5.United Kingdom Short-Acting Insulin Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Drugs
      • 6.3.5.2.2.By Application

7.North America Short-Acting Insulin Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Drugs
  • 7.2.2.By Application
  • 7.2.3.By Country
• 7.3.North America: Country Analysis
  • 7.3.1.United States Short-Acting Insulin Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Drugs
      • 7.3.1.2.2.By Application
  • 7.3.2.Mexico Short-Acting Insulin Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Drugs
      • 7.3.2.2.2.By Application
  • 7.3.3.Canada Short-Acting Insulin Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Drugs
      • 7.3.3.2.2.By Application

8.South America Short-Acting Insulin Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Drugs
  • 8.2.2.By Application
  • 8.2.3.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Short-Acting Insulin Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Drugs
      • 8.3.1.2.2.By Application
  • 8.3.2.Argentina Short-Acting Insulin Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Drugs
      • 8.3.2.2.2.By Application
  • 8.3.3.Colombia Short-Acting Insulin Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Drugs
      • 8.3.3.2.2.By Application

9.Middle East and Africa Short-Acting Insulin Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Drugs
  • 9.2.2.By Application
  • 9.2.3.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Short-Acting Insulin Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Drugs
      • 9.3.1.2.2.By Application
  • 9.3.2.Saudi Arabia Short-Acting Insulin Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Drugs
      • 9.3.2.2.2.By Application
  • 9.3.3.UAE Short-Acting Insulin Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Drugs
      • 9.3.3.2.2.By Application

10.Market Trends Developments

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Recent Developments
• 11.2.Product Launches
• 11.3.Mergers Acquisitions

12.Global Short-Acting Insulin Market: SWOT Analysis

13.Porter's Five Forces Analysis

• 13.1.Competition in the Industry
• 13.2.Potential of New Entrants
• 13.3.Power of Suppliers
• 13.4.Power of Customers
• 13.5.Threat of Substitute Product

14.Competitive Landscape

• 14.1.Novo Nordisk AS
  • 14.1.1.1.Business Overview
  • 14.1.1.2.Company Snapshot
  • 14.1.1.3.Product Services
  • 14.1.1.5.Financials (In case of listed)
  • 14.1.1.6.Recent Developments
  • 14.1.1.7.SWOT Analysis
• 14.2.Sanofi SA
• 14.3.Eli Lilly Co
• 14.4.Biocon Ltd
• 14.5.Wockhardt Ltd
• 14.6.Boehringer Ingelheim International GmbH
• 14.7.Julphar Pharma Inc
• 14.8.United Laboratories International Holdings Limited
• 14.9.Tonghua Dongbao Pharmaceutical Co. Ltd.

15.Strategic Recommendations

16. About Us Disclaimer